Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
Bristol-Myers Squibb (BMY) Stock Price & Analysis
10,019 Followers
BMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$47.03 - $68.01
Previous Close$47.84
Volume2.73M
Average Volume (3M)15.86M
Market Cap
$97.49B
Enterprise Value$124.51B
Total Cash (Recent Filing)$12.28B
Total Debt (Recent Filing)$39.77B
Price to Earnings (P/E)12.4
Beta0.37
Next Earnings
Apr 25, 2024EPS Estimate
-$4.45Last Dividend Ex-Date
Apr 04, 2024Dividend Yield4.79%
Share Statistics
EPS (TTM)3.86
Shares Outstanding2,022,193,411
10 Day Avg. Volume11,316,287
30 Day Avg. Volume15,856,954
Standard Deviation0.06
R-Squared0.13
Alpha0.00194
Financial Highlights & Ratios
Price to Book (P/B)-5.17
Price to Sales (P/S)2.15
Price to Cash Flow (P/CF)5.70
P/FCF Ratio5.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.79
Enterprise Value/Gross Profit3.63
Enterprise Value/Ebitda7.08
Forecast
1Y Price Target
$54.25Price Target Upside12.79% Upside
Rating ConsensusHold
Number of Analyst Covering14
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Drug Efficacy And SafetyThe 52-week data revealed continued improvement in schizophrenia symptoms with KarXT and no additional safety concerns.
Pipeline DevelopmentKarXT pipeline expansion indicates potential growth areas beyond schizophrenia.
Valuation & Investment OpportunityBMY's valuation remains at levels rarely seen for a Pharma company, representing an attractive longer-term opportunity.
Bears Say
Competitive ChallengesCarvykti had clearer support from the ODAC compared to Abecma, which may impact Abecma's competitive position.
Drug Efficacy ConcernsReleased FDA briefing documents raise significant concerns about Abecma's early higher incidence of death.
Revenue ForecastAnalyst projects a sharp decrease in 2024E EPS due to the Karuna IPR&D charge and lower core revenue.
---
Ownership Overview
0.30% Insiders
24.04% Mutual Funds
22.73% Other Institutional Investors
52.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $47.03 and its highest was $68.01 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Apr 25, 2024 which is in 7 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Feb 02, 2024. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.554 by $0.146.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 4.79%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is -$4.45.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,026,758,700 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.7 in its last earnings report, beating expectations of $1.554. Following the earnings report the stock price went up 0.083%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 1B.
---
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$54.25 (12.79% Upside)
$54.25 (12.79% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.32%
12-Months-Change
Fundamentals
Return on Equity
26.53%
Trailing 12-Months
Asset Growth
-1.72%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BMY Company Deck
---
BMY Earnings Call
Q4 2024
0:00 / 0:00
---
BMY Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
BMY Stock 12 Months Forecast
Average Price Target
$54.25
▲(12.79% Upside)
Technical Analysis
Best Analysts Covering BMY
1 Year
1 Year Success Rate
15/16 ratings generated profit
1 Year Average Return
+14.88%
reiterated a sell rating 10 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +14.88% per trade.
---